Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia

Objective: BCR-ABL1 kinase domain (KD) mutations can lead to resistance to first- and second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). Here, we present the first report of the spectrum of mutations in the BCR-ABL1 KD of CML patients from Azerbaijan.Materials and...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Aypara Hasanova, Chingiz Asadov, Nigar Karimova, Aytan Shirinova, Gunay Aliyeva, Zohra Alimirzoyeva
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2023-12-01
Edice:	Pathology and Oncology Research
Témata:	chronic myeloid leukemia mutation tyrosine kinase inhibitor resistance kinase domain BCR-ABL
On-line přístup:	https://www.por-journal.com/articles/10.3389/pore.2023.1611518/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!